Press contact

Manuela Schildwächter
Tel +49 30 68905 1414
Fax +49 30 68905 961414
E-Mail press@biotronik.com
Link to Contact Form

1/21/15

Trial Examines Safety of Full-Body MRI Scans on ICDs, including DX Technology

BIOTRONIK Concludes Enrollment in Phase C of its ProMRI ICD Study
LAKE OSWEGO, Oregon, January 21, 2015 - BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced today that Phase C of its ProMRI® study completed patient enrollment in December 2014. This phase investigates the safety of implantable cardioverter defibrillator (ICD) devices in patients undergoing full-body magnetic resonance imaging (MRI) scans. The BIOTRONIK DX system is also included in the study that investigates the effects of cardiac and thoracic spinal scans. BIOTRONIK is one of only two companies in the U.S. currently approved to conduct these studies, which aim to broaden diagnostic options for cardiac device patients.

more...

1/21/15

Schülerinnen besuchen ihre Mentorinnen bei BIOTRONIK

Mehr Frauen in die Medizintechnik
BERLIN, 20. Januar 2015 – Im Rahmen der langjährigen Zusammenarbeit mit dem „Club Lise“ hießen die BIOTRONIK Mitarbeiterinnen Sofia Binias und Ulrike Heiden naturwissenschaftlich interessierte Schülerinnen am Hauptsitz des Unternehmens in Berlin-Neukölln willkommen. Die Besucherinnen erhielten einen Einblick in den Berufsalltag der beiden Physikerinnen und konnten bei einer anschließenden Werksführung hautnah miterleben, wie Herzschrittmacher und implantierbare Kardioverter-Defibrillatoren (ICDs) entwickelt und hergestellt werden.

more...

1/14/15

Trial to Demonstrate Efficacy of AlCath Flux eXtra Gold Ablation Catheter in Reducing the Incidence of Harmful Thromboemboli

BIOTRONIK Announces First Enrollments in New Study Evaluating Reduction of Thromboembolic Events via GoldTip Ablation
BERLIN, Germany, January 14, 2015 – BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced today the first enrollments in its prospective, multi-center, international Reduce-TE Pilot study (Reduction of AF Ablation Induced Thrombo-Embolic Incidence). The study will assess the ability of the advanced irrigated ablation catheter AlCath Flux eXtra Gold to reduce the incidence of silent microemboli (SME). SME are a complication associated with catheter ablation of the pulmonary veins, a common treatment for atrial fibrillation (AF). The BIOTRONIK ablation catheter features a GoldTip and a 3-D irrigation system which study investigators believe can diminish the number of SME via optimized cooling, thereby improving patient safety.

more...

1/14/15

Studie soll die Wirksamkeit des Ablationskatheters AlCath Flux eXtra Gold von BIOTRONIK zur Reduktion der Inzidenz von mikroembolischen Ereignissen belegen

Reduziert GoldTip-Katheterablation thromboembolische Ereignisse? Erster Patient in Reduce-TE Studie eingeschlossen
Berlin, 14. Januar 2015 – BIOTRONIK, ein führender Hersteller kardiovaskulärer Medizintechnik, gab heute den Start der prospektiven, multizentrischen, internationalen Studie „Reduce-TE“ (Reduction of AF Ablation Induced Thrombo-Embolic Incidence) bekannt. Im Rahmen der Pilotstudie wird geprüft, ob der gespülte Ablationskatheter der zweiten Generation AlCath Flux eXtra Gold dazu beitragen kann, die Inzidenz von asymptomatischen mikroembolischen Ereignissen (abgekürzt SME für „silent micro-embolic events“) zu senken.

more...

Choose Year

Use the filters to sort the available press releases:

Submit
PrintPrint Page MailE-Mail Page Text Size